11β-Hydroxysteroid deshydrogenase: A multi-faceted enzyme

Journal of Hypertension

Volumn 23, Issue 1, 2005, Pages 29-31

  Persu, Alexandre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; HYDROCORTISONE;

BINDING AFFINITY; EDITORIAL; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GENETIC ASSOCIATION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; ENZYMOLOGY; KIDNEY; METABOLISM; NOTE; RENOVASCULAR HYPERTENSION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; HUMANS; HYPERTENSION, RENAL; KIDNEY;

EID: 12344268887     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200501000-00007     Document Type: Editorial

References (28)

1. Stewart PM, Edwards CR. The cortisol-cortisone shuttle and hypertension. J Steroid Biochem Mol Biol 1991; 40:501-509.
2. White PC, Tomaotsu M, Agarwal A. 11beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Rev 1997; 18:135-155.
3. Ferrari P. Genetics of the mineralocorticoid system in primary hypertension. Curr Hypertens Rep 2002; 4:18-24.
4. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993; 341:339-341.
5. Stewart PM, Rogerson FM, Mason JI. Type 211 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab 1995; 80: 885-890.
6. Mune T, White PC. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension 1996; 27: 1193-1199.
7. Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, etal. Mutants of 11 beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 1999; 34:638-642.
8. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, et al. Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. Am J Hum Genet 1998; 63:370-379.
9. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, el al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci USA 1998; 95:10200-10205.
10. Lavery GG, Ronconi V, Draper N, Rabbitt EH, Lyons V, Chapman KE, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene Hypertension 2003; 42:123-129.
11. Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 1993; 39:221-227.
12. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25:67-70.
13. Litchfield WR, Hunt SC, Jeunemaitre X, Fisher ND, Hopkins PN, Williams RR, et al. Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. Hypertension 1998; 31:569-574.
14. Iki K, Miyamori I, Hatakeyama H, Yoneda T, Takeda Y, Takeda R, et al. The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Steroids 1994; 59:656-660.
15. Takeda Y, Miyamori I, Iki K, Inaba S, Furukawa K, Hatakeyama H, et al. Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 1996; 27:197-201.
16. Santini DL, Lorenzo BJ, Koufis T, Reidenberg MM. Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics. Am J Hypertens 1995; 8:516-519.
17. Ferrari P, Sansonnens A, Dick B, Frey FJ. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 2001; 38:1330-1336.
18. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, et al. CA-Repeat polymorphism in intron 1 of HSD11B2; effects on gene expression and salt sensitivity. Hypertension 2000; 36:187-194.
19. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999; 84:3745-3749.
20. Bocchi B, Kenouch S, Lamarre-Cliche M, Muffat-Joly M, Capron MH, Fiet J, et al. Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension 2004; 43:803-808.
21. Brand E, Kato N, Chatelain N, Krozowski ZS, Jeunemaitre X, Corrol P, et al. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) gene in human essential hypertension. J Hypertens 1998; 16:1627-1633.
22. Lo YH, Sheff MF, Latif SA, Ribeiro C, Silver H, Brem AS, et al. Kidney 11 beta-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine. Hypertension 1997; 29:500-505.
23. + on glycyrrhetinic acid-like factors (kidney 11beta-(HSD2)-GALFs) in human essential hypertension. Hypertension 1998 469-472.
24. Carvajal CA, Romero DG, Mosso LM, Gonzalez AA, Campino C, Montera J, Fardella CE. Biochemical and genetic characterization of 11β-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. J Hypertens 2005; 23:71-77.
25. Agarwal AK. Transcriptional influence of two poly purine-pyrimidine tracts located in the HSD11B2 (11 beta-hydroxysteroid dehydrogenase type 2 gene). Endocr Res 2001; 27:1-9.
26. MacKenzie MA, Hoefnagels WH, Jansen RW, Benraad TJ, Kloppenborg PW. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab 1990; 70: 1637-1643.
27. Stormer FC, Reistad R, Alexander J. Glycyrrhizic acid in liquorice - evaluation of health hazard. Food Chem Toxicol 1993; 31:303-312.
28. Epstein MT, Espiner EA, Donald RA, Hughes H. Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J 1977; 1:488-490.